Bone Biologics Co. Expected to Post Q1 2023 Earnings of ($0.15) Per Share (OTC:BBLG)

Bone Biologics Co. (OTC:BBLGGet Rating) – Investment analysts at Zacks Small Cap issued their Q1 2023 earnings per share (EPS) estimates for Bone Biologics in a research note issued to investors on Thursday, September 15th. Zacks Small Cap analyst B. Sorensen forecasts that the company will post earnings per share of ($0.15) for the quarter. The consensus estimate for Bone Biologics’ current full-year earnings is ($0.61) per share. Zacks Small Cap also issued estimates for Bone Biologics’ Q2 2023 earnings at ($0.20) EPS, Q3 2023 earnings at ($0.22) EPS, Q4 2023 earnings at ($0.15) EPS, Q1 2024 earnings at ($0.30) EPS and Q2 2024 earnings at ($0.45) EPS.

Bone Biologics Stock Performance

Shares of OTC:BBLG opened at $1.20 on Monday. Bone Biologics has a twelve month low of $1.08 and a twelve month high of $7.12. The business has a fifty day moving average of $1.33 and a 200-day moving average of $1.71.

Hedge Funds Weigh In On Bone Biologics

An institutional investor recently bought a new position in Bone Biologics stock. Vanguard Group Inc. bought a new stake in Bone Biologics Co. (OTC:BBLGGet Rating) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 33,461 shares of the company’s stock, valued at approximately $93,000. Vanguard Group Inc. owned approximately 0.32% of Bone Biologics as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 0.46% of the company’s stock.

Bone Biologics Company Profile

(Get Rating)

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration.

Recommended Stories

Earnings History and Estimates for Bone Biologics (OTC:BBLG)

Receive News & Ratings for Bone Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bone Biologics and related companies with's FREE daily email newsletter.